C2N Diagnostic, a St Louis, MO-based company which specializes in developing Alzheimer’s disease-specific fluid biomarker tests, received a $15M program-related investment from GHR Foundation (GHR).
The company intends to use the funds for new tests specific to tau tangle pathology.
These new tests offer a potential alternative to tau PET tracers and will focus on a combination of tau-based blood biomarkers, including MTBR-tau, which are important indicators of pathological tau tangles and neurites associated with Alzheimer’s disease. These blood biomarkers may aid in differential diagnosis of clinical Alzheimer’s disease among people with cognitive symptoms, biologically stage the disease, and help inform the development of tau-directed therapeutics by providing insights into tau pathology.
Led by CEO Dr. Joel Braunstein, C2N Diagnostics is a diagnostics company which aims to provide clinical laboratory services and advanced diagnostic solutions in the field of brain health. Its mass spectrometry-based biomarker services and products are used for:
- clinical decision-making to improve patient care, including diagnosis and treatment monitoring;
- optimizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration;
- providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health.
GHR Foundation funding is in addition to the recent announcement that C2N has received a groundbreaking investment up to $7.025 million from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator initiative. The Diagnostics Accelerator investment is devoted to developing a decentralized clinical mass spectrometry solution to enable high-performance Alzheimer’s disease testing worldwide.
FinSMEs
30/09/2024